A Phase 2 interventional study of Benzoyl peroxide gel and Clindamycin gel in Acne Vulgaris, sponsored by Stiefel, a GSK Company. Completed at 16 sites in United States. Open to participants aged 12 Years to 45 Years. Per ClinicalTrials.gov, last updated 2017-03-06.
Sponsored by Stiefel, a GSK Company (part of GlaxoSmithKline) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 33 studies testing Benzoyl Peroxide in Acne Vulgaris — none open to participants now, 1 under way, none of them phase 3. Benzoyl Peroxide · Acne Vulgaris.
Among the 33 studies testing Benzoyl Peroxide in Acne Vulgaris, this one is the 10th largest by enrollment, is one of 4 that started in 2008, is one of 2 in phase 2, and was the 6th registered.
791 studies on the registry are indexed under Acne Vulgaris; 93 are open to participants now.
Browse Acne Vulgaris studies →None of the 33 studies testing Benzoyl Peroxide in Acne Vulgaris is open now. The open studies under Acne Vulgaris, anywhere →
Benzoyl Peroxide: first FDA approval 1984 (BENZAMYCIN). What it is approved for, and how studies give it, is on its page →
Of the 46 Acne Vulgaris studies recruiting now, 16 (35%) set no upper age limit and 29 (63%) stop at 75 or younger; 21 take children under 18; 17 take healthy volunteers.
This study: 12 Years to 45 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
33 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 4 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 591 is above the median of 70 across 673 interventional studies indexed under Acne Vulgaris.
Median enrollment 90 across the 33 interventional studies. Of the 28 that completed or were terminated, 24 (86%) have results posted.
This tab as a report to print or save as PDF → With an account.
26 of 33 have an industry lead sponsor. The 10 most frequent:
This study is registered under Stiefel, a GSK Company, one of the names counted as GlaxoSmithKline. Under that name alone:
Stiefel, a GSK Company is the lead sponsor of 56 studies on the registry; none are open to participants now.
42 studies in Acne Vulgaris by GlaxoSmithKline: none open now, none under way, none of them phase 3. Of 42 finished, 24 (57%) have results posted.
Among the 42 studies in Acne Vulgaris by GlaxoSmithKline, this one is the 7th largest by enrollment, is one of 6 that started in 2008, is one of 2 in phase 2, and was the 3rd registered.
GlaxoSmithKline’s Acne Vulgaris studies by the year they started, since 2004.
None of the studies under way reaches primary completion within a year.
Among the 33 studies testing Benzoyl Peroxide in Acne Vulgaris, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among GlaxoSmithKline’s 42 in Acne Vulgaris:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Benzoyl peroxide, clindamycin and tazarotene are known to be effective treatment alternative for acne vulgaris. The purpose of this study is to assess the safety and efficacy of a combination product including these actives for the treatment of acne vulgaris.
You may be suitable to take part in this study because you have acne vulgaris on your face. Acne vulgaris usually affects the face, but it can also affect the skin on the chest, arms, legs, and back.
The study subjects must have acne vulgaris and will apply study drug to their face for 12 weeks.
Study visits will occur at baseline (day 1) and at weeks 2, 4, 8, and 12. Subjects will be assessed at every visit to determine how the study drug is working. Safety will be assessed by evaluation of adverse events (AEs), vital signs, physical examinations, and withdrawals from the study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Benzoyl peroxide/clindamycin gel + tazarotene cream
Drug: Benzoyl peroxide gel · Drug: Clindamycin gel · Drug: Tazarotene cream
Benzoyl peroxide/clindamycin gel + vehicle cream
Drug: Benzoyl peroxide gel · Drug: Clindamycin gel · Drug: Vehicle cream
Benzoyl peroxide gel + tazarotene cream
Drug: Benzoyl peroxide gel · Drug: Tazarotene cream
Clindamycin gel + tazarotene cream
Drug: Clindamycin gel · Drug: Tazarotene cream
Vehicle gel+ tazarotene cream
Drug: Tazarotene cream · Drug: Vehicle gel
Vehicle gel + vehicle cream
Drug: Vehicle gel · Drug: Vehicle cream
5% benzoyl peroxide in a gel applied topically once a day
1% clindamycin phosphate applied topically once a day
0.1 % tazarotene in a cream applied topically once a day
Vehicle gel is an identical gel without the active ingredients
Vehicle cream is an identical cream without the active ingredients
Absolute Change in Lesion Counts (Total, Inflammatory, and Non-inflammatory) From Baseline to Week 12
The investigator or designee took count of inflammatory lesions (papules, pustules, nodules and cysts \[only post-Baseline\]) (ILC), noninflammatory lesions (open and closed comedones) (NILC) and total lesions (TLC) at Baseline, Weeks 2, 4, 8, and 12. Lesion counts were confined to the face. Each of 3 lesion counts (total, inflammatory and non-inflammatory) was analyzed using an analysis of covariance (ANCOVA) model with terms for treatment, center, Baseline value and treatment-by-center interaction. If the interaction was not significant at 0.1 level, this interaction was excluded in ANCOVA model. Day 1 (Visit 1) was defined as Baseline. Only participants available at specified timepoints were analyzed (represented by n=X in the category titles).
Time frame: Baseline and up to Week 12
Proportion of Participants With a Minimum 2-grade Improvement in the Investigator's Static Global Assessment (ISGA) Score From Baseline to Week 12
An ISGA was obtained at Baseline and at Weeks 2, 4, 8, and 12. The scores range from 0-5 (0=clear skin with no inflammatory or non-inflammatory lesions; 5=very severe with many non-inflammatory and inflammatory lesions and more than a few nodular lesions (may have cystic lesions). The higher score indicates more severe. The area considered for the ISGA was confined to the face. When possible, the same efficacy assessor performed all ISGA assessments on the same participant at all visits. Day 1 (Visit 1) was defined as Baseline. Only participants available at specified time points were analyzed.
Time frame: Baseline and up to Week 12
Percent Change From Baseline to Week 12 in Each of 3 Lesion Counts (Total, Inflammatory, and Non-inflammatory)
The investigator or designee took count of inflammatory lesions (papules, pustules, nodules and cysts) (ILC), noninflammatory lesions (open and closed comedones) (NILC) and total lesions (TLC) at Baseline, Weeks 2, 4, 8, and 12. Lesion counts were confined to the face. Each of 3 lesion counts (total, inflammatory and non-inflammatory) was analyzed using an analysis of covariance (ANCOVA) model with terms for treatment, center, Baseline value and treatment-by-center interaction. If the interaction was not significant at 0.1 level, this interaction was excluded in ANCOVA model. Day 1 (Visit 1) was defined as Baseline. Only participants available at specified timepoints were analyzed (represented by n=X in the category titles).
Time frame: Baseline and up to Week 12
Proportion of Participants With an ISGA Score of 0 or 1 at Week 12
An ISGA was obtained at Baseline and at Weeks 2, 4, 8, and 12. The scores range from 0-5 (0=clear skin with no inflammatory or non-inflammatory lesions; 5=very severe with many non-inflammatory and inflammatory lesions and more than a few nodular lesions (may have cystic lesions). The higher score indicates more severe. The area considered for the ISGA was confined to the face. When possible, the same efficacy assessor performed all ISGA assessments on the same participant at all visits. Day 1 (Visit 1) was defined as Baseline. Only participants available at specified time points were analyzed.
Time frame: Week 12
In this multi-center, double-blind, vehicle controlled study, participants were assigned to one of the six treatment groups in a 2:2:2:2:2:1 ratio for 12 weeks.
| Milestone | Benzoyl Peroxide/Clindamycin + Tazarotene | Benzoyl Peroxide/Clindamycin + Vehicle Cream | Benzoyl Peroxide Gel + Tazarotene | Clindamycin Gel + Tazarotene | Vehicle Gel + Tazarotene | Vehicle Gel + Vehicle Cream |
|---|---|---|---|---|---|---|
| Started | 106 | 105 | 107 | 108 | 106 | 55 |
| Completed | 85 | 90 | 92 | 99 | 87 | 47 |
| Not completed | 21 | 15 | 15 | 9 | 19 | 8 |
| Withdrew: Adverse event | 2 | 0 | 2 | 2 | 3 | 1 |
| Withdrew: Lost to follow-up | 5 | 7 | 5 | 5 | 7 | 0 |
| Withdrew: Lack of efficacy | 1 | 3 | 0 | 0 | 1 | 0 |
| Withdrew: Non-compliance with study treatment | 1 | 1 | 2 | 0 | 1 | 0 |
| Withdrew: Withdrawal by subject | 6 | 1 | 5 | 1 | 5 | 7 |
| Withdrew: Protocol violation | 6 | 3 | 1 | 1 | 2 | 0 |
The investigator or designee took count of inflammatory lesions (papules, pustules, nodules and cysts \[only post-Baseline\]) (ILC), noninflammatory lesions (open and closed comedones) (NILC) and total lesions (TLC) at Baseline, Weeks 2, 4, 8, and 12. Lesion counts were confined to the face. Each of 3 lesion counts (total, inflammatory and non-inflammatory) was analyzed using an analysis of covariance (ANCOVA) model with terms for treatment, center, Baseline value and treatment-by-center interaction. If the interaction was not significant at 0.1 level, this interaction was excluded in ANCOVA model. Day 1 (Visit 1) was defined as Baseline. Only participants available at specified timepoints were analyzed (represented by n=X in the category titles).
| Lesion count | Benzoyl Peroxide/Clindamycin + Tazarotene | Benzoyl Peroxide/Clindamycin + Vehicle Cream | Benzoyl Peroxide Gel + Tazarotene | Clindamycin Gel + Tazarotene | Vehicle Gel + Tazarotene | Vehicle Gel + Vehicle Cream |
|---|---|---|---|---|---|---|
| ILC, n=101, 103, 105, 105, 104, 52 | -16.8 ± 14.35 | -18.1 ± 14.45 | -18.9 ± 12.84 | -18.8 ± 11.49 | -14.5 ± 12.76 | -8.96 ± 12.63 |
| NILC, n=101, 103, 105, 105, 104, 52 | -33.0 ± 23.94 | -24.9 ± 33.41 | -37.1 ± 29.70 | -37.5 ± 29.51 | -33.0 ± 25.89 | -18.9 ± 28.41 |
| TLC, n=101, 103, 105, 105, 104, 52 | -49.8 ± 31.78 | -43.0 ± 42.24 | -56.0 ± 34.99 | -56.3 ± 35.42 | -47.6 ± 33.32 | -27.8 ± 35.06 |
An ISGA was obtained at Baseline and at Weeks 2, 4, 8, and 12. The scores range from 0-5 (0=clear skin with no inflammatory or non-inflammatory lesions; 5=very severe with many non-inflammatory and inflammatory lesions and more than a few nodular lesions (may have cystic lesions). The higher score indicates more severe. The area considered for the ISGA was confined to the face. When possible, the same efficacy assessor performed all ISGA assessments on the same participant at all visits. Day 1 (Visit 1) was defined as Baseline. Only participants available at specified time points were analyzed.
| Percentage of participants | Benzoyl Peroxide/Clindamycin + Tazarotene | Benzoyl Peroxide/Clindamycin + Vehicle Cream | Benzoyl Peroxide Gel + Tazarotene | Clindamycin Gel + Tazarotene | Vehicle Gel + Tazarotene | Vehicle Gel + Vehicle Cream |
|---|---|---|---|---|---|---|
| Proportion of Participants With a Minimum 2-grade Improvement in the Investigator's Static Global Assessment (ISGA) Score From Baseline to Week 12 | 22 | 22 | 31 | 36 | 20 | 5 |
The investigator or designee took count of inflammatory lesions (papules, pustules, nodules and cysts) (ILC), noninflammatory lesions (open and closed comedones) (NILC) and total lesions (TLC) at Baseline, Weeks 2, 4, 8, and 12. Lesion counts were confined to the face. Each of 3 lesion counts (total, inflammatory and non-inflammatory) was analyzed using an analysis of covariance (ANCOVA) model with terms for treatment, center, Baseline value and treatment-by-center interaction. If the interaction was not significant at 0.1 level, this interaction was excluded in ANCOVA model. Day 1 (Visit 1) was defined as Baseline. Only participants available at specified timepoints were analyzed (represented by n=X in the category titles).
| Percent change | Benzoyl Peroxide/Clindamycin + Tazarotene | Benzoyl Peroxide/Clindamycin + Vehicle Cream | Benzoyl Peroxide Gel + Tazarotene | Clindamycin Gel + Tazarotene | Vehicle Gel + Tazarotene | Vehicle Gel + Vehicle Cream |
|---|---|---|---|---|---|---|
| ILC, n=101, 103, 105, 105, 104, 52 | -58.3 ± 45.57 | -62.4 ± 39.33 | -62.4 ± 34.83 | -65.7 ± 33.38 | -49.0 ± 40.90 | -33.5 ± 41.10 |
| NILC, n=101, 103, 105, 105, 104, 52 | -58.0 ± 29.97 | -39.2 ± 51.29 | -60.6 ± 35.00 | -61.2 ± 31.60 | -53.1 ± 30.56 | -29.5 ± 44.05 |
| TLC, n=101, 103, 105, 105, 104, 52 | -59.1 ± 29.96 | -47.9 ± 38.89 | -62.0 ± 29.42 | -63.4 ± 28.75 | -51.8 ± 29.18 | -31.5 ± 37.59 |
An ISGA was obtained at Baseline and at Weeks 2, 4, 8, and 12. The scores range from 0-5 (0=clear skin with no inflammatory or non-inflammatory lesions; 5=very severe with many non-inflammatory and inflammatory lesions and more than a few nodular lesions (may have cystic lesions). The higher score indicates more severe. The area considered for the ISGA was confined to the face. When possible, the same efficacy assessor performed all ISGA assessments on the same participant at all visits. Day 1 (Visit 1) was defined as Baseline. Only participants available at specified time points were analyzed.
| Percentage of participants | Benzoyl Peroxide/Clindamycin + Tazarotene | Benzoyl Peroxide/Clindamycin + Vehicle Cream | Benzoyl Peroxide Gel + Tazarotene | Clindamycin Gel + Tazarotene | Vehicle Gel + Tazarotene | Vehicle Gel + Vehicle Cream |
|---|---|---|---|---|---|---|
| Proportion of Participants With an ISGA Score of 0 or 1 at Week 12 | 33 | 31 | 27 | 39 | 22 | 13 |
Collected over Serious adverse events (SAEs) and non-serious adverse events (AEs) were collected from Day 1 up to Day 89.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Benzoyl Peroxide/Clindamycin + Tazarotene | — | 0/106 (0%) | 25/106 (23.6%) |
| Benzoyl Peroxide/Clindamycin + Vehicle Cream | — | 0/105 (0%) | 22/105 (21%) |
| Benzoyl Peroxide Gel + Tazarotene | — | 0/107 (0%) | 24/107 (22.4%) |
| Clindamycin Gel + Tazarotene | — | 0/108 (0%) | 18/108 (16.7%) |
| Vehicle Gel + Tazarotene | — | 0/106 (0%) | 29/106 (27.4%) |
| Vehicle Gel + Vehicle Cream | — | 0/55 (0%) | 12/55 (21.8%) |
| Event | Benzoyl Peroxide/Clindamycin + Tazarotene | Benzoyl Peroxide/Clindamycin + Vehicle Cream | Benzoyl Peroxide Gel + Tazarotene | Clindamycin Gel + Tazarotene | Vehicle Gel + Tazarotene | Vehicle Gel + Vehicle Cream |
|---|---|---|---|---|---|---|
| NasopharyngitisInfections and infestations | 3/106 | 3/105 | 3/107 | 5/108 | 4/106 | 3/55 |
| Upper respiratory tract infectionInfections and infestations | 5/106 | 4/105 | 5/107 | 2/108 | 4/106 | 1/55 |
| Application site irritationGeneral disorders | 1/106 | 0/105 | 3/107 | 4/108 | 2/106 | 0/55 |
| Application site painGeneral disorders | 0/106 | 0/105 | 2/107 | 0/108 | 0/106 | 2/55 |
| SinusitisInfections and infestations | 1/106 | 1/105 | 2/107 | 0/108 | 1/106 | 2/55 |
| EpistaxisRespiratory, thoracic and mediastinal disorders | 0/106 | 0/105 | 3/107 | 0/108 | 0/106 | 0/55 |
| Application site pruritusGeneral disorders | 0/106 | 0/105 | 0/107 | 0/108 | 2/106 | 1/55 |
| Allergy to arthropod biteImmune system disorders | 2/106 | 0/105 | 0/107 | 0/108 | 1/106 | 0/55 |
| InfluenzaInfections and infestations | 1/106 | 0/105 | 0/107 | 0/108 | 2/106 | 0/55 |
| HeadacheNervous system disorders | 0/106 | 0/105 | 1/107 | 0/108 | 2/106 | 0/55 |
| Age, Continuous(Years) | Benzoyl Peroxide/Clindamycin + Tazarotene | Benzoyl Peroxide/Clindamycin + Vehicle Cream | Benzoyl Peroxide Gel + Tazarotene | Clindamycin Gel + Tazarotene | Vehicle Gel + Tazarotene | Vehicle Gel + Vehicle Cream | Total |
|---|---|---|---|---|---|---|---|
| Mean | 19.7 ± 6.6 | 19.7 ± 6.9 | 20.2 ± 7.3 | 19.2 ± 6.2 | 21.7 ± 8.4 | 19.8 ± 6.6 | 20.1 ± 7.1 |
| Gender(Participants) | Benzoyl Peroxide/Clindamycin + Tazarotene | Benzoyl Peroxide/Clindamycin + Vehicle Cream | Benzoyl Peroxide Gel + Tazarotene | Clindamycin Gel + Tazarotene | Vehicle Gel + Tazarotene | Vehicle Gel + Vehicle Cream | Total |
|---|---|---|---|---|---|---|---|
| Female | 58 | 56 | 60 | 60 | 65 | 35 | 334 |
| Male | 48 | 49 | 47 | 48 | 41 | 20 | 253 |
| Race/Ethnicity, Customized(Participants) | Benzoyl Peroxide/Clindamycin + Tazarotene | Benzoyl Peroxide/Clindamycin + Vehicle Cream | Benzoyl Peroxide Gel + Tazarotene | Clindamycin Gel + Tazarotene | Vehicle Gel + Tazarotene | Vehicle Gel + Vehicle Cream | Total |
|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 1 | 0 | 0 | 0 | 0 | 0 | 1 |
| Asian | 8 | 14 | 5 | 6 | 9 | 5 | 47 |
| Black | 23 | 16 | 24 | 15 | 14 | 8 | 100 |
| Multiracial | 10 | 11 | 9 | 8 | 8 | 5 | 51 |
| Native Hawaiian or Other Pacific Islander | 1 | 1 | 1 | 0 | 1 | 0 | 4 |
| White | 63 | 63 | 68 | 79 | 74 | 37 | 384 |
The record gives a start of Jun 2008, a primary completion of Mar 2009 and a completion of Mar 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Mar 2017, 8 years after primary completion. A results delay was requested in Sep 2010.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Benzoyl Peroxide · Clindamycin · Tazarotene